Cargando…
Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy.
The present study evaluated serial serum measurements of tissue polypeptide-specific antigen (TPS) in comparison with prostate-specific antigen (PSA) for assessment of tumour progression in patients with advanced prostate cancer receiving intermittent androgen suppression therapy (IAS). Twenty-three...
Autores principales: | Theyer, G., Holub, S., Dürer, A., Andert, S., Haberl, I., Theyer, U., Hamilton, G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223501/ https://www.ncbi.nlm.nih.gov/pubmed/9166947 |
Ejemplares similares
-
Measurement of bone turnover in prostate cancer patients receiving intermittent androgen suppression therapy
por: Theyer, Gerhard, et al.
Publicado: (2010) -
Type I Collagen Synthesis Marker Procollagen I N-Terminal Peptide (PINP) in Prostate Cancer Patients Undergoing Intermittent Androgen Suppression
por: Hamilton, Gerhard, et al.
Publicado: (2011) -
Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation
por: Brady-Nicholls, Renee, et al.
Publicado: (2020) -
HOXB13 is co-localized with androgen receptor to suppress androgen-stimulated prostate-specific antigen expression
por: Kim, Sin Do, et al.
Publicado: (2010) -
Expression of androgen receptor and prostate-specific antigen in male breast carcinoma
por: Kidwai, Noman, et al.
Publicado: (2004)